Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading.
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading.
Visit NMRDinfo.com for more information.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
The document discusses real-time continuous glucose monitoring (rtCGM) and its clinical implementation aspects. It provides a brief history of glucose monitoring technologies and outlines some key barriers to self-monitoring of blood glucose. The document then discusses several currently available rtCGM systems, including the Dexcom G6, Guardian Connect, and FreeStyle Libre. It notes their sensor wear times, calibration requirements, alarm features, and accuracy levels. The document also discusses using rtCGM data to generate ambulatory glucose profiles and the limitations of rtCGM technologies, such as sensor interference and lag times between interstitial and blood glucose readings.
Recent Innovations in Applications and Devices to Tackle DiabetesEMMAIntl
Approximately 463 million people on Earth are affected by Diabetes, a disease in which the body’s ability to produce or use the produced insulin to regulates blood glucose levels is impaired. Consistent high glucose levels can lead to serious conditions significantly affecting the heart, kidneys, nerves, eyes, and blood vessels. In the US, Diabetes is the 7th highest cause of death with effects including retinopathy (blindness), kidney failure, and heart stroke...
- The document discusses the history and evolution of glucose monitoring technologies from urine testing to current continuous glucose monitoring systems (CGM).
- It provides details on the advantages of real-time CGM (rtCGM) over self-monitoring of blood glucose (SMBG), including continuous readings without pain and ability to detect trends and prevent hypoglycemic events.
- The document compares different CGM systems like Dexcom G5 and G6, Medtronic Guardian Connect, and FreeStyle Libre Pro interms of features, calibration needs, and accuracy.
- It describes how sensor-augmented insulin pumps that suspend insulin delivery can help minimize hypoglycemia, and discusses hybrid closed-loop systems like
Alertgy was founded to develop a noninvasive blood sugar monitor using new sensor technologies. The monitor would continuously track blood sugar levels without finger pricks and enable tighter control of diabetes. It has the potential to disrupt the market given the large and growing diabetes population. Clinical trials of a prototype showed promising results compared to traditional finger prick monitors. Alertgy is seeking investment to further develop the technology and bring the product to market over the next three years.
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading.
Visit NMRDinfo.com for more information.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
The document discusses real-time continuous glucose monitoring (rtCGM) and its clinical implementation aspects. It provides a brief history of glucose monitoring technologies and outlines some key barriers to self-monitoring of blood glucose. The document then discusses several currently available rtCGM systems, including the Dexcom G6, Guardian Connect, and FreeStyle Libre. It notes their sensor wear times, calibration requirements, alarm features, and accuracy levels. The document also discusses using rtCGM data to generate ambulatory glucose profiles and the limitations of rtCGM technologies, such as sensor interference and lag times between interstitial and blood glucose readings.
Recent Innovations in Applications and Devices to Tackle DiabetesEMMAIntl
Approximately 463 million people on Earth are affected by Diabetes, a disease in which the body’s ability to produce or use the produced insulin to regulates blood glucose levels is impaired. Consistent high glucose levels can lead to serious conditions significantly affecting the heart, kidneys, nerves, eyes, and blood vessels. In the US, Diabetes is the 7th highest cause of death with effects including retinopathy (blindness), kidney failure, and heart stroke...
- The document discusses the history and evolution of glucose monitoring technologies from urine testing to current continuous glucose monitoring systems (CGM).
- It provides details on the advantages of real-time CGM (rtCGM) over self-monitoring of blood glucose (SMBG), including continuous readings without pain and ability to detect trends and prevent hypoglycemic events.
- The document compares different CGM systems like Dexcom G5 and G6, Medtronic Guardian Connect, and FreeStyle Libre Pro interms of features, calibration needs, and accuracy.
- It describes how sensor-augmented insulin pumps that suspend insulin delivery can help minimize hypoglycemia, and discusses hybrid closed-loop systems like
Alertgy was founded to develop a noninvasive blood sugar monitor using new sensor technologies. The monitor would continuously track blood sugar levels without finger pricks and enable tighter control of diabetes. It has the potential to disrupt the market given the large and growing diabetes population. Clinical trials of a prototype showed promising results compared to traditional finger prick monitors. Alertgy is seeking investment to further develop the technology and bring the product to market over the next three years.
(1) Nemaura Medical is developing a non-invasive, flexible continuous glucose monitor called SugarBEAT that consists of a daily disposable skin patch, transmitter, and app. It aims to expand CGM use beyond insulin users to all diabetics and pre-diabetics, a total addressable market of $82 billion.
(2) Interim data from Nemaura's FDA clinical trial showed SugarBEAT achieved a mean absolute relative difference (MARD) of 8.77% for 1-point calibration and 7.97% for 2-point calibration, outperforming Dexcom G5. Commercial launch in the UK is expected in Q4 2018 with FDA approval and US launch anticipated
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical (NASDAQ: NMRD)
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetic
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for Infra V’s Smart Watch. This watch can continuously monitor glucose using a non-invasive spectrometric process, which enables better management of diabetes through more timely insulin injections. The watch replaces the widely used finger-pricking method that is painful for users and thus discourages effective monitoring of a patient’s glucose levels. The watch is also smaller and cheaper than other methods of continuous monitoring. These slides describe the specific value proposition for patients and doctors other aspects of the business model such as the method of value capture, scope of activities, and method of strategic control.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
The document provides information on professional continuous glucose monitoring (CGM) systems, including their value, use, and safety. It discusses three CGM systems - FreeStyle Libre Pro, Dexcom G4 Platinum Professional, and Medtronic iPro. For each system, it summarizes how it works, calibration needs, data display and interpretation, wear time, and important safety information. The document also provides tips for training patients on CGM use and examples of CGM reports to facilitate therapy changes.
Continuous glucose monitoring market ,trends, size, share, industry analysis,...Parmeshwar Karkale
The document discusses the global continuous glucose monitoring (CGM) market. It provides an overview of key factors driving market growth, including rising diabetes incidence rates and technological innovations like artificial pancreas devices. The CGM market is expected to grow from $194.8 million in 2012 to $568.5 million by 2020. The report analyzes the market by device, application, age group, and region. It also profiles major industry players and their strategies.
Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Diabetes technology has advanced significantly over time, starting with insulin pumps and continuous glucose monitors (CGM), and now including hybrid closed loop systems that both monitor glucose and deliver insulin. The goals of diabetes technology include improving glycemic control as measured by time in range, reducing hypoglycemia and hyperglycemia, and providing insights to help prevent complications through improved self-management. Current and emerging technologies like smart insulin pens, implantable insulin pumps, and wearable glucose meters continue pushing the field forward to better mimic a natural pancreas.
Continuous Glucose Monitoring Systems Market PPT: Growth, Outlook, Demand, Ke...IMARC Group
The global continuous glucose monitoring systems market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
More Info:- https://www.imarcgroup.com/continuous-glucose-monitoring-systems-market
The document summarizes the history of glucose testing from ancient times to modern flash glucose monitoring systems like the FreeStyle Libre. It traces the evolution from urine and blood testing using chemical reactions to today's enzyme-based biosensors and continuous glucose monitors. The FreeStyle Libre is highlighted as a breakthrough that eliminates finger pricks, provides accurate readings with a 1-second scan, and addresses the need for more frequent glucose data through its 14-day sensor wear and Ambulatory Glucose Profile reports. Clinical trials aim to demonstrate its benefits in improving outcomes and gaining insurance reimbursement.
This presentation was delivered at the 2017 JDRF TypeOneNation Summit in Tulsa, OK on 1/28/2017. It is a summary of insulin pumps, CGMs, data display and management software, and other aspects of technology related to type 1 diabetes.
Researchers are making progress toward the artificial pancreas (AP) with 2016 focusing on real-world testing of algorithms. Key areas of interest for 2017 include transparency of researcher methods and data, effort required by patients, and reimbursement discussions. Continuous glucose monitoring accuracy and wear time remain barriers, as do pump reliability and immune responses. Both algorithmic and heuristic approaches are being studied, with personalization seen as important. Success has also come from grassroots integration and sharing of existing technologies.
VTG is a client-value multiplier that develops revolutionary solutions for clients. It has 10 proprietary solutions across medical, food service, automotive/industrial, and energy/utilities markets with a potential $7.1B in royalty revenue. VTG is seeking partners to commercialize its energy/utilities portfolio, including intuitive flow meters for fluids, gases, and electricity that can meter, monitor, and control distribution and usage. VTG projects its current product portfolio could generate over $6B in passive lifetime royalty revenue.
2018 Oklahoma Type One Nation Tech PresentationClayton McCook
The document summarizes diabetes technology updates presented by Clayton McCook, DVM at the 2018 Type One Nation Summit. It discusses several insulin pump brands including Insulet's Omnipod, Medtronic's Paradigm and MiniMed pumps, and Tandem's T-Slim pumps. Continuous glucose monitoring technologies from Dexcom and Medtronic are also summarized. Future products in development including automated insulin delivery systems are mentioned. Data management platforms and diabetes management apps are briefly outlined.
This document discusses the use of Ambulatory Glucose Profile (AGP) and Time in Range (TIR) metrics for diabetes management. It provides guidance on interpreting AGP reports, which simplify complex continuous glucose monitoring (CGM) data into snapshots like TIR. TIR measures the percentage of time spent within, above, and below target glucose ranges and is a useful measurement that complements A1C. The document recommends increasing TIR and reducing time below range as primary goals for effective glucose control. It also presents different patient scenarios and indicators for using AGP and TIR data in diabetes management.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
More Related Content
Similar to Nmrd (NASDAQ: NMRD) Investor Presentation May 2019
(1) Nemaura Medical is developing a non-invasive, flexible continuous glucose monitor called SugarBEAT that consists of a daily disposable skin patch, transmitter, and app. It aims to expand CGM use beyond insulin users to all diabetics and pre-diabetics, a total addressable market of $82 billion.
(2) Interim data from Nemaura's FDA clinical trial showed SugarBEAT achieved a mean absolute relative difference (MARD) of 8.77% for 1-point calibration and 7.97% for 2-point calibration, outperforming Dexcom G5. Commercial launch in the UK is expected in Q4 2018 with FDA approval and US launch anticipated
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical (NASDAQ: NMRD)
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetic
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for Infra V’s Smart Watch. This watch can continuously monitor glucose using a non-invasive spectrometric process, which enables better management of diabetes through more timely insulin injections. The watch replaces the widely used finger-pricking method that is painful for users and thus discourages effective monitoring of a patient’s glucose levels. The watch is also smaller and cheaper than other methods of continuous monitoring. These slides describe the specific value proposition for patients and doctors other aspects of the business model such as the method of value capture, scope of activities, and method of strategic control.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
The document provides information on professional continuous glucose monitoring (CGM) systems, including their value, use, and safety. It discusses three CGM systems - FreeStyle Libre Pro, Dexcom G4 Platinum Professional, and Medtronic iPro. For each system, it summarizes how it works, calibration needs, data display and interpretation, wear time, and important safety information. The document also provides tips for training patients on CGM use and examples of CGM reports to facilitate therapy changes.
Continuous glucose monitoring market ,trends, size, share, industry analysis,...Parmeshwar Karkale
The document discusses the global continuous glucose monitoring (CGM) market. It provides an overview of key factors driving market growth, including rising diabetes incidence rates and technological innovations like artificial pancreas devices. The CGM market is expected to grow from $194.8 million in 2012 to $568.5 million by 2020. The report analyzes the market by device, application, age group, and region. It also profiles major industry players and their strategies.
Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Diabetes technology has advanced significantly over time, starting with insulin pumps and continuous glucose monitors (CGM), and now including hybrid closed loop systems that both monitor glucose and deliver insulin. The goals of diabetes technology include improving glycemic control as measured by time in range, reducing hypoglycemia and hyperglycemia, and providing insights to help prevent complications through improved self-management. Current and emerging technologies like smart insulin pens, implantable insulin pumps, and wearable glucose meters continue pushing the field forward to better mimic a natural pancreas.
Continuous Glucose Monitoring Systems Market PPT: Growth, Outlook, Demand, Ke...IMARC Group
The global continuous glucose monitoring systems market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
More Info:- https://www.imarcgroup.com/continuous-glucose-monitoring-systems-market
The document summarizes the history of glucose testing from ancient times to modern flash glucose monitoring systems like the FreeStyle Libre. It traces the evolution from urine and blood testing using chemical reactions to today's enzyme-based biosensors and continuous glucose monitors. The FreeStyle Libre is highlighted as a breakthrough that eliminates finger pricks, provides accurate readings with a 1-second scan, and addresses the need for more frequent glucose data through its 14-day sensor wear and Ambulatory Glucose Profile reports. Clinical trials aim to demonstrate its benefits in improving outcomes and gaining insurance reimbursement.
This presentation was delivered at the 2017 JDRF TypeOneNation Summit in Tulsa, OK on 1/28/2017. It is a summary of insulin pumps, CGMs, data display and management software, and other aspects of technology related to type 1 diabetes.
Researchers are making progress toward the artificial pancreas (AP) with 2016 focusing on real-world testing of algorithms. Key areas of interest for 2017 include transparency of researcher methods and data, effort required by patients, and reimbursement discussions. Continuous glucose monitoring accuracy and wear time remain barriers, as do pump reliability and immune responses. Both algorithmic and heuristic approaches are being studied, with personalization seen as important. Success has also come from grassroots integration and sharing of existing technologies.
VTG is a client-value multiplier that develops revolutionary solutions for clients. It has 10 proprietary solutions across medical, food service, automotive/industrial, and energy/utilities markets with a potential $7.1B in royalty revenue. VTG is seeking partners to commercialize its energy/utilities portfolio, including intuitive flow meters for fluids, gases, and electricity that can meter, monitor, and control distribution and usage. VTG projects its current product portfolio could generate over $6B in passive lifetime royalty revenue.
2018 Oklahoma Type One Nation Tech PresentationClayton McCook
The document summarizes diabetes technology updates presented by Clayton McCook, DVM at the 2018 Type One Nation Summit. It discusses several insulin pump brands including Insulet's Omnipod, Medtronic's Paradigm and MiniMed pumps, and Tandem's T-Slim pumps. Continuous glucose monitoring technologies from Dexcom and Medtronic are also summarized. Future products in development including automated insulin delivery systems are mentioned. Data management platforms and diabetes management apps are briefly outlined.
This document discusses the use of Ambulatory Glucose Profile (AGP) and Time in Range (TIR) metrics for diabetes management. It provides guidance on interpreting AGP reports, which simplify complex continuous glucose monitoring (CGM) data into snapshots like TIR. TIR measures the percentage of time spent within, above, and below target glucose ranges and is a useful measurement that complements A1C. The document recommends increasing TIR and reducing time below range as primary goals for effective glucose control. It also presents different patient scenarios and indicators for using AGP and TIR data in diabetes management.
Similar to Nmrd (NASDAQ: NMRD) Investor Presentation May 2019 (20)
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
2. Forward-Looking Statement
This presentation includes forward-looking statements that are subject to many risks and uncertainties. These
forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies,
can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,”
and similar words. These statements involve many risks and uncertainties that may cause actual results to differ
from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with
the Securities and Exchange Commission (the “Commission”), including the risks identified under the section
captioned “Risk Factors” in Nemaura’s Quarterly Report on Form 10-Q filed with the Commission on February
11, 2019 and in Nemaura’s Form 10-K filed with the Commission on June 12, 2018. Nemaura disclaims any
obligation to update information contained in these forward-looking statements whether as a result of new
information, future events, or otherwise.
NASDAQ: NMRD 2
3. Investment Highlights
NASDAQ: NMRD 3
✓ World’s first non-invasive continuous glucose monitor (CGM), targeting $179B+ opportunity:
• $69B+ type II diabetic market & $50B+ pre-diabetic market & $60B+ wearable health-tech market
✓ Anticipate near-term FDA submission & CE approval
✓ Lowest price, high recurring margin model, with lowest COGS per CGM patch in the industry
✓ Growing IP portfolio with over 30 issued & pending patents
✓ Platform BEAT™ diagnostic technology with robust product pipeline:
• Launching continuous lactate monitoring (CLM) near term, targeting $60B+ wearable tech market
• Pipeline of four other products including non-invasive continuous alcohol monitoring (CAM)
✓ Proven management team with successful track records
✓ Clean capital structure with no long-term debt
4. CGM vs. Finger Stick & A1c
• CGM currently targets insulin users – unmet need for non-insulin users
• Insulin users (20% of diabetics) have traditionally used multiple (typically 6-8) daily
finger stick glucose readings to guide insulin dosage decisions
• Non-insulin users (80% of diabetics) have traditionally mostly used periodic A1c
readings (every 3-6 months) to manage glucose levels. A1c is derived from a lab
blood test providing a single value representing the average glucose level over past
60-90 days
• Continuous Glucose Monitoring (CGM) transforms insulin dosage decisions by
providing real-time, constant glucose readings, typically at 5 min intervals
• These 5 minute readings (12 per hour) accumulate over the day to provide an
Ambulatory Glucose Profile (AGP chart) based on 288 readings over 24 hours
• CGM transforms glucose control by switching focus from limited ‘gold standard’ A1c
metric to more meaningful ‘time in range’ (TIR) metric measuring how much time
per day glucose kept within normal range
NASDAQ: NMRD 4
CGM adoption enables
new standard of care:
• Insulin users:
Improve insulin
dosage decisions
and reduce finger
stick frequency
• Non insulin users:
Better manage
glucose by adopting
‘time in range’ (TIR)
alongside A1c
5. Limitations of A1c: ‘Time in Range’ (TIR) Matters
• Diabetics aim to keep A1c below 7% (8.6 mmol/L)
• Three people can have identical 7% A1c with wildly
differing ‘TIR’ (see chart)
• CGM uniquely allows diabetics to view Ambulatory
Glucose Profile (AGP) chart. AGP chart enables TIR.
• AGP enables real time behavior changes to minimize
glucose fluctuations thereby increasing TIR
• Diabetes can be put into remission if glucose levels are
constantly maintained in range
• The FDA Device Division (CDRH) recognizes the validity
of ‘time in range’
• Pre-diabetics can also delay or avoid onset of diabetes
by improving TIR
NASDAQ: NMRD 5
6. • SugarBEAT has three target markets:1
- $69B+ TAM Type II diabetics (95% of all diabetics)
- $50B+ TAM Pre-diabetics – approximately 3x population
- $60B+ TAM Wearable HealthTech market – low carb / weight
loss / fitness2
Continuous Glucose Monitoring (CGM): TAM
NASDAQ: NMRD
6
U.S. CGM Market Overview 1
• U.S. has the largest number of CGM users globally (630k in 2018)
• Only 2.6% of 25M US diagnosed diabetics used CGM in 2018
• U.S. annual CGM usage increased by 117% in 2018
• 30% of U.S. type I diabetics use CGM
• 3% of U.S. type II insulin users use CGM
• CGM usage amongst non-insulin diabetics negligible
• U.S. has 84M pre-diabetics
1 PiperJaffray Company Note DXCM Sep 5 2018
2 Juniper Research Digital Health Report Jan 14 2019
Type II (non-insulin)
($31B+ TAM)
Pre-Diabetic
($50B+ TAM)
Wearable Health-Tech
($60B+ TAM)
Type II (insulin)
($38B+ TAM)
Type I (insulin)
($12B+ TAM)
7. SugarBEAT® CGM
• World’s first non-invasive CGM – sits on top of the skin
and does not puncture the skin
• Daily disposable adhesive skin-patch connected to a
rechargeable transmitter
• Smartphone App displays glucose readings every five
minutes for periods up to 24 hours
• Designed to help users better manage their glucose
levels by spending more time in range
• Insulin users can adjunctively use SugarBEAT® when
calibrated with a finger-stick glucose reading
• CE Mark achieved on predecessor device (wrist-watch
format) in Q1 2016
NASDAQ: NMRD 77
8. How SugarBEAT® Works
• SugarBEAT® passes a mild, non-perceptible electric current across the skin
• Painlessly draws a small amount of glucose molecules out of the interstitial fluid just below the
top layer of skin into a chamber within the patch
• The rechargeable transmitter measures glucose levels within the chamber, and
transmits this data every five minutes via Bluetooth
• Using a proprietary algorithm, the app then displays
this data as glucose value on smart phone / device
• Watch SugarBEAT® video at:
https://sugarbeat.com/introducing-sugarbeat/
NASDAQ: NMRD 8
9. SugarBEAT® Competitive Advantages
1. Non invasive - competitors use invasive devices, and a large needle to
puncture the skin to insert the sensor
2. Flexible – wear when you choose for periods up to 24 hours. Competitors require
continuous wear for 10-90 day periods
3. Hypoallergenic – uses gentler silicon adhesive and change daily location of patch
4. Affordable – less than one sixth monthly cost of leading competitor
NASDAQ: NMRD
9
Current Products
SugarBEAT
No
~ $30/month
<24 hour wear
(removable)
Yes
(Needle)
~$100/month
14 day wear
Yes
(Needle)
~180/month
10 day wear
Yes
(Implant)
~ $240/month
90 day wear
Cost
CGM
Product
Invasive?
Flexibility
10. Lowest Price High Recurring Margin Lowest COGS Model
NASDAQ: NMRD 10
• Amongst CGMs, SugarBEAT® achieves lowest price, high recurring gross margins & lowest COGS
• SugarBEAT® does not need to be worn on continuous day basis greatly amplifying price saving
• Anticipated gross margins ~70%** driven by lowest COGS per CGM patch in industry
* Indicative pricing - to be confirmed
**Excluding gross margin sharing agreement with distributor in Europe
• Non-Insulin users = $30 / month*
• 8 Patches / month
• Annual Subscription
• Inclusive of transmitter and recharger
• Insulin users = $55 / month*
• 16 Patches / month
• Annual Subscription
• Inclusive of transmitter and recharger
• SugarBEAT® lowest monthly cost CGM:
• SugarBEAT® $30 monthly cost* (8 patches)
• Abbot Libre $100 monthly cost
• Dexcom G6 $180 monthly cost
• Senseonics $240 monthly cost
11. SugarBEAT® Clinical Data
• Recently completed clinical studies to support FDA submission
• The clinical studies used were split between Type I and Type II diabetics
• Consisted of 75 patients over 225 patient days
• Generated over 12,000 paired data points, with blood samples taken via catheter every 15 minutes over
a 12-hour period for three non-consecutive days for each patient
• Study design was based on two previous pre-sub meetings Nemaura held with the FDA, ensuring
that the study meet adequacy requirements to provide statistically valid results
• The clinical study results indicated a MARD (Mean Absolute Relative Difference) of 11.92% (with a
lower figure denoting greater accuracy), using a single point finger stick calibration
• No device-related adverse events were noted
NASDAQ: NMRD 11
12. SugarBEAT® Regulatory Pathway
• U.S. FDA De-Novo 510(k)
✓ Successfully completed the clinical studies needed to support
FDA submission for approval of SugarBEAT® in the USA
✓ Currently preparing the dossier for FDA submission
• European CE Mark
✓ Working closely with British Standards Institute (BSI), the
Company’s designated European Notified Body, a global
leader in accreditation services, on a Fast Track application
✓ On track for CE Mark approval followed by commercial
launch later this year
NASDAQ: NMRD 12
De-Novo 510(k)
• Lower risk (Class II graded medium risk)
• Quicker review process compared with
PMA which is Class III graded (higher risk)
• The recent De-Novo and subsequent
510(k) by Dexcom provide evidence that
current FDA thinking on invasive CGM
devices for therapeutic use are suitable
for classification as Class II
• SugarBEAT® is non-invasive and
adjunctive, and therefore lower risk
13. Intellectual Property
• Building an extensive intellectual property portfolio, to position
the Company to become a leader in the non-invasive CGM space
• The Company has over thirty patents (~70% approved and ~30% pending)
spanning the following six patent families:
1. Sensor related
2. Algorithm and methods of using the CGM data
3. Algorithm related - allowing sensing cycles to be reduced
4. Devices & methods to enhance glucose sensing
5. Methods to enhance glucose sensing
6. Devices and methods to extract glucose
• The Company anticipates filing of a further 60 patents over the course of the next 18 months
NASDAQ: NMRD 13
15. Current Product Pipeline
NASDAQ: NMRD 15
Product Key Features Market
SugarBEAT Gen II • Include pediatric cover
• Improved accuracy (MARD)
• Longer patch wear time (72 hours)
• Type II Diabetics
• Pre-Diabetics
• Wearable Health-Tech
Continuous Lactate Monitoring
(anticipated launch Q4 2019)
• Worlds only non-invasive skin patch
for continuous lactate monitoring
• Determines appropriate training
intensity levels and monitors
progression
• Athletes
• Fitness
• Wearable Health-Tech market
expected to be worth $60B+ by
20231
1 Juniper Research Digital Health Report Jan 14 2019
16. Planned Product Pipeline
NASDAQ: NMRD 16
Product Uses Diagnostics
Alcohol Monitoring Support personal health goals, and
provide warnings prior to driving, and
provide physicians with individual
drinking habits
Prevention of progression to alcohol
related diseases.
Prostaglandin Screening for inflammatory irritants in
formulations during drug and cosmetic
development
Inflammation
Lactate Lactate monitoring in intensive care Anaerobic
Metabolism
Various Monitoring the impact of drug
treatment for treatment-regimen
calibration and pharmacokinetics
Treatment
Regimen
Optimization
Phenylalanine Phenylalanine monitoring to ensure
that the level is sufficiently suppressed
Phenylketonuria (PKU)
17. Senior Management
Dr. Faz Chowdhury, CEO
Dr. Chowdhury is in charge of research and development of the core technologies, product development, innovation and commercialization.
Prior to establishing the Company, Dr. Chowdhury was the founder and CEO of Microneedle Technologies and Nemaura Pharma Limited where
he played a pivotal role in the development, manufacture and launch of a microneedle device used in skin clinics, which is also currently being
evaluated for skin cancer drug delivery. Dr. Chowdhury has been responsible for negotiating licensing deals for a transdermal patch to treat
Alzheimer’s disease. Additionally, he was involved in negotiations for out-licensing patches to treat Parkinson’s and Hypertension, and in-
licensing complementary technologies. Dr. Chowdhury originally trained as a pharmaceutical scientist and has an MSc in Microsystems and
Nanotechnology from Cranfield University, and a Doctorate from the University of Oxford on nano-drug delivery.
Bashir Timol, Chief Business Officer
Mr. Timol co-founded, managed and funded several biotech and life science companies, and led the investment consortium that provided
capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the
University of Central Lancashire, UK.
Dr. Fred Schaebsdau, Strategy and Business Development Advisor
Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries,
which started in 2004 during his tenure with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams
responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From 2016 until 2019, he was the General Manager of Dexcom
Germany, which during his leadership became the fastest growing organization in Dexcom’s history achieving triple digit revenue and new
patient growth every year. Two generations of CGM, G5 and G6, were successfully launched and negotiations with public insurers completed,
which resulted in full reimbursement for >85% of the German population. From 2009 until 2015, at Roche Diabetes Care, he was Sr. VP & Head
of Global Strategy and Business Development, completing several strategic acquisitions, partnerships and licensing deals. In 2015, he founded
his own firm as exclusive distributor in Europe, Middle East and Africa for UniStrip®, the world’s first generic blood glucose test strip. Since
2015, he has been member of the Advisory Board of Peppermint Venture Partners.
NASDAQ: NMRD 17
18. Investment Highlights
NASDAQ: NMRD 18
✓ World’s first non-invasive continuous glucose monitor (CGM), targeting $179B+ opportunity:
• $69B+ type II diabetic market & $50B+ pre-diabetic market & $60B+ wearable health-tech market
✓ Anticipate near-term FDA submission & CE approval
✓ Lowest price, high recurring margin model, with lowest COGS per CGM patch in the industry
✓ Growing IP portfolio with over 30 issued & pending patents
✓ Platform BEAT™ diagnostic technology with robust product pipeline:
• Launching continuous lactate monitoring (CLM) near term, targeting $60B+ wearable tech market
• Pipeline of four other products including non-invasive continuous alcohol monitoring (CAM)
✓ Proven management team with successful track records
✓ Clean capital structure with no long-term debt
19. Key Statistics
NASDAQ: NMRD 19
Ticker: NMRD
Exchange: NASDAQ
Share price (as of 4/26/2019): $1.02
Common shares outstanding: 207.5 M
Market Capitalization: $211.7 M
Options and Warrants (10M @ $0.50 and 1.9M @ $1.04): 11.9M
Total Potential Shares Outstanding: 221.7 M
Fiscal year-end: March 31
Insider ownership (fully diluted): 58%